Compare WFF & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WFF | BMRA |
|---|---|---|
| Founded | 1984 | 1971 |
| Country | Malaysia | United States |
| Employees | 138 | 54 |
| Industry | Miscellaneous manufacturing industries | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 7.5M |
| IPO Year | N/A | 1995 |
| Metric | WFF | BMRA |
|---|---|---|
| Price | $2.07 | $2.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.0K | ★ 15.1K |
| Earning Date | 05-24-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,311,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.18 | $1.87 |
| 52 Week High | $29.22 | $4.60 |
| Indicator | WFF | BMRA |
|---|---|---|
| Relative Strength Index (RSI) | 66.15 | 56.85 |
| Support Level | $0.38 | $2.33 |
| Resistance Level | $2.08 | $2.40 |
| Average True Range (ATR) | 0.17 | 0.13 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 89.33 | 70.12 |
WF Holding Ltd is a manufacturer of FRP products based in Malaysia. It has been providing high-quality and durable FRP products to various industries, including, among others, chemical processing, water and wastewater treatment, and power generation. Its products range from tanks, pipes, ducts, gratings and other custom-made FRP products. The company uses advanced production technology and equipment and has obtained various certifications. Its manufacturing capabilities allow the company to design and fabricate products that meet the specific needs of its clients, ensuring high-quality and reliable performance.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.